Racetam

Piracetam

2-Oxo-1-pyrrolidineacetamide

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

1,200–4,800 mg

watchEffect Window

2-4 weeks of continuous use for cognitive benefits.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Piracetam is the original racetam compound with clinical use history in some countries. It is used for cortical myoclonus and for cognitive symptom protocols, with variable evidence for dementia.

Clinical evidence supports piracetam for cortical myoclonus. Studies in cognitive impairment show mixed results, with some suggesting modest improvements in memory and attention and others showing minimal benefit. Minority applications include dyslexia and vertigo protocols in certain regions. Tolerability is generally good, but the evidence base is heterogeneous and less supportive for cognitive enhancement in healthy adults.

Modulates AMPA and NMDA receptors to increase glutamatergic signaling, enhances cholinergic transmission, and increases neuronal membrane fluidity.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest but consistent cognitive improvement in elderly with cognitive decline or dementia (meta-analytic support)

Secondary Outcomes

  • Reduces breath-holding spells in children
  • Reduces cortical myoclonus

Safety

Contraindications and Interactions

Contraindications

  • Severe renal impairment (renally cleared)
  • Huntington's disease

Side effects

  • Headache (most common, often due to inadequate choline)
  • GI upset
  • Insomnia
  • Irritability

Interactions

  • May potentiate anticoagulants
  • Enhances effects of amphetamines and thyroid hormones

Avoid if

  • Severe renal impairment
  • Huntington's disease

Evidence

Study-level References

piracetam-SRC-001Meta-analysis of RCTs
Sourceopen_in_new

Waegemans T, et al. "Clinical efficacy of piracetam in cognitive impairment: a meta-analysis." Dement Geriatr Cogn Disord. 2002.

Population: Older adults with cognitive impairment/dementia

Key findings: The meta-analysis demonstrated a statistically significant difference in favor of piracetam over placebo for global improvement in older subjects with cognitive impairment.

Paper content

The meta-analysis demonstrated a statistically significant difference in favor of piracetam over placebo for global improvement in older subjects with cognitive impairment.

piracetam-SRC-002Systematic review and meta-analysis.
Sourceopen_in_new

Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2024;243:108358. doi:10.1016/j.clineuro.2024.108358. PMID:38878641.

Population: Adults with memory impairment across 18 clinical trials.

Dose protocol: Various piracetam doses versus placebo across 18 trials (886 adults)

Key findings: Numerical trend favoring piracetam (SMD 0.75) but not statistically significant (P=0.12) with very high heterogeneity (I-squared 96%).

Notes: Most comprehensive modern quantitative synthesis. The null overall finding tempers older positive Cochrane-era results.

Paper content

This systematic review and meta-analysis pooled 18 clinical trials (886 patients) to evaluate piracetam versus placebo for memory impairment in adults. The overall effect favored piracetam numerically (SMD 0.75) but did not reach statistical significance (P=0.12), with very high heterogeneity (I-squared 96%). The authors concluded that piracetam's impact on memory function could not be definitively established and called for further research. The analysis is useful as the most comprehensive modern quantitative synthesis on this question, and its null overall finding tempers the older Cochrane-era literature that showed more positive pooled results in global clinical impression scores.

piracetam-SRC-003Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Sharawat IK, Dawman L, Panda P, Panda PK. Efficacy of piracetam in children with breath-holding spells: a systematic review and meta-analysis. Eur J Pediatr. 2024;184(1):89. doi:10.1007/s00431-024-05926-4. PMID:39692893.

Population: Children with breath-holding spells across 5 RCTs.

Dose protocol: Oral piracetam versus placebo across 5 RCTs in children with breath-holding spells

Key findings: Significantly higher favorable response rates at 1, 2, and 3 months, with more complete attack cessation.

Notes: Meta-analytic confirmation of piracetam efficacy for this specific pediatric indication.

Paper content

This meta-analysis pooled 5 RCTs (437 children) evaluating oral piracetam for breath-holding spells. Piracetam showed significantly higher favorable response rates at 1, 2, and 3 months compared to placebo, with more complete attack cessation and greater reductions in average spell frequency. Safety profiles were comparable between groups. The authors also noted potential enhancement through DHA co-administration. This study strengthens the evidence for piracetam in pediatric breath-holding spells, a condition where iron supplementation is the usual first-line approach but not always sufficient.

Guides

Setup

Help